We studied the physiometabolic effects of a mitochondrial DNA (mtDNA) heteroplasmic point mutation, the A Gtransition associated with maternally inherited myopathy and cardiomyopathy. To eliminate the possible influence of the autochthonous nuclear gene set, we fused myoblast-derived cytoplasts of a patient with a human tumoral cell line deprived of mtDNA (Rho0). The presence and amount of the mutant G3260 vs the wild-type A326" were measured by solid phase minisequencing. We observed a marked reduction of the percentage of mutant mtDNA in the culture system compared with that measured in the donor's muscle biopsy, suggesting the presence of negative selection against the mutation. Furthermore, stable mitotic segregation of the two mtDNA populations was observed in 18 of 19 transformant clones, suggesting the presence of intraorganelle and possibly intracellular homoplasmy in the precursor cells of the donor. Several indexes of mtDNA-related respiratory capacity, including oxygen consumption, complex I-and complex IV-specific activities, and lactate production, were markedly abnormal in the clones containing a high proportion of mutant mtDNA, as compared with those containing homoplasmic wild-type mtDNA, possibly because of impaired mitochondrial protein synthesis. We conclude that (a) the A -G31 transition is indeed responsible for the mitochondrial disorder identified in the donor patient, and (b) transformant cybrid system gives direct evidence of the mitochondrial origin of a genetic disorder and should be adopted for the evaluation of the pathogenic potential of the mtDNA mutations. (J. Clin.
Introduction
We have recently described a maternally inherited adult-onset syndrome, characterized clinically by the variable combination Address correspondence to Dr. Massimo Zeviani, Department of Biochemistry and Genetics, Istituto Nazionale Neurologico C. Besta, via Celoria 1 1, Milano, Italy 1-20133. Receivedfor publication 6 August 1993 and in revisedform 22 October 1993.
of skeletal and heart muscle failure (MIMyCa, ' maternally inherited myopathy and cardiomyopathy), and molecularly by the presence of a heteroplasmic point mutation in mitochondrial DNA (mtDNA) transfer RNA (tRNA)Teu(IR) gene ( 1) . The pathogenicity of the mutation, an A --G transition at mtDNA nucleotide position 3260 (2) , was based on the following evidence: (a) the mutation affected a highly conserved nucleotide and disrupted an A-T pair in the proposed anticodon stem of the tRNA secondary structure, presumably perturbing the stability of the tRNA IU(UUR) cloverleaf; (b) the mutation segregated specifically with the disorder; and (c) there were significant correlations between the proportion of the mtDNA that was of the mutant form and the activities (normalized for citrate synthase activity) oftwo mtDNA-dependent respiratory enzymes (i.e., complex I and complex IV) and the maximum oxygen consumption, a physiologic index of aerobic metabolism.
However, the relevance ofthis mutation for the pathogenesis of MIMyCa could still be questioned, since: (a) it was reported in a single family; (b) the method used for quantitation ofthe proportions ofthe two populations of mtDNA, based on densitometry of PCR products, was rather inaccurate; (c) a possible influence of autochthonous nuclear gene products could not be excluded, since biochemical and molecular analysis was performed on patients' muscle biopsies, and the physiometabolic investigations (i.e., measurement of maximal oxygen consumption) were carried out in vivo; and (d) similar to other point mutations in tRNA genes, the A -*G 3260 transition was proposed to affect the mitochondrial oxidative phosphorylation (OXPHOS) by compromising the ability of mitochondria to translate their own genes. However, no direct demonstration of the effects on mitochondrial translation was offered since a suitable ex vivo system was not available at that time.
To answer these objections and to study the effects of the G3260 mutation in a fully controlled ex vivo system, we prepared transformant cybrid clones (3) by fusing cytoplasts derived from a G321-positive patient with tumor cells deprived of mtDNA (rho' cells). The relative amount ofthe mutant G3260 was measured using solid phase minisequencing (SPMS), a suitable method for accurate quantification of mtDNA point mutations (4) . The presence of the mutation was then correlated with several biochemical, metabolic, and molecular-genetic indexes of mitochondrial respiratory capacity. Using this approach, we present here strong evidence that the MIMyCa mutation is indeed the cause of the OXPHOS impairment found in our patients, most likely because of defective translation of mitochondrial polypeptides. As an important corollary, this study shows that transmitochondrial cybrids can be used to verify whether the presence of a given mtDNA mutation is necessary and sufficient to cause a human disease.
Methods
Patient. The MIMyCa patient was a 23-yr-old man (for details see subject III-1 in reference 1) who suffered from heart failure and muscle weakness due to skeletal myopathy with ragged-red fibers. He had an enlarged liver, bilateral ankle edema, and an enlarged left ventricle. Densitometric quantitation showed that 90% of mtDNA extracted from skeletal muscle was mutant.
Cell culture. An mtDNA-less cell line was isolated after treatment of human osteosarcoma 143B thymidine kinase-deficient (TK-) cells (American Type Culture Collection, Rockville, MD) with 50 ng/ml ethidium bromide for 2 mo, as described (3) . Rho' cells were grown in DME containing 4.5 Askanas and Engel (5) with minor modifications. Myoblasts were grown in F14 medium (Seromed, Berlin, Germany) containing 6 g/ liter glucose and supplemented with 15% FBS, 10 ng/ml EGF, 50 ng/ ml fibroblast growth factor (FGF), 10 ,g/ml insulin, and 50 jig/ml uridine.
To obtain transmitochondrial cybrids, -2-5 X 105 myoblasts were enucleated by centrifugation in the presence ofcytochalasin B (10 ,gg/ml), and then were cocultured and fused with 106 rho0 cells by briefly adding a solution of 50% (wt/vol) polyethylene glycol and 10% DMSO in phosphate buffer. 24 h after fusion, cybrids were replated and were continuously grown in DME supplemented with 5% dialyzed FBS and 100 yg/ml BrdU. 14-16 d after fusion, cybrids were plated at low density for selection ofcell clones in the same medium used for the rho0 cells. DNA analysis. Total DNA was extracted from the cybrid clones, as described previously (6) . RFLP analysis was used to distinguish the mtDNA ofthe donor cells from that ofthe parental 143B cells, since an HaeIII restriction site at position 16517 was absent in the former (7) and present in the latter mtDNA.
Characterization of the nuclear DNA was carried out using the highly polymorphic repetitive sequence Dl IS533 present on chromosome I lq as described (8) .
RFLP analysis with XmnI of DNA fragments obtained by mispaired PCR according to Zeviani et al. (1) was routinely used to identify the G32 mutation. Quantification ofthe mutation was performed using SPMS (4 supplemented with 50 /Ag/ml uridine, 100 Ag/ml emetine, and 5% dialyzed FBS as described by Chomyn et al. (9) . Equal amounts (50 ,g) of total cellular protein measured by the method ofLowry et al. ( 10) were electrophoresed through a 15% SDS Laemmli polyacrylamide gel ( 11 ), and the mitochondrial translation products were visualized by fluorography on Kodak X-Omat AR films. Assignment of the mitochondrial translation products was based on similarity of the labeling pattern to that described elsewhere (7, 9 cells in 300 Ml of DME lacking glucose (9) . Rotenone-sensitive NADH-CoQ reductase-(ND, complex I) and cytochrome c oxidase-(CO, complex IV) specific activities were measured in duplicate on cell homogenates after 2x sonication for 3 s, as described previously ( 12) .
To measure the lactic acid production, 5 X I05 cells of each clone were plated on 60-mm petri dishes and were incubated in 2 ml RPMI-1640 lacking phenol red and supplemented with 2 g/liter glucose, 50 Mg/ml uridine, 4% FBS, and 2 mM glutamine. After incubation for 48 h, lactic acid concentration was measured in the culture medium according to Noll ( 13), and lactic acid production was expressed as micromoles per milligram of total cell protein.
Statistics (Fig. 1) The qualitative patterns of mitochondrial translation products were virtually identical in the four clones, irrespective of the presence of the mutation. This result differs from that reported for the mitochondrial encephalomyopathy lactic acidosis and strokelike episodes G3243 mutation, in which a slight increase in the electrophoretic mobility of NDI was observed (7), as well as for the myoclonic epilepsy and ragged-red fibers (MERRF) G8343 mutation, in which a prominent extra band was observed running immediately below ND4 (9) .
From a quantitative standpoint, the M clone P28 showed a generalized decrease in the incorporation of [31S]methionine into the mitochondrial-encoded polypeptides. The decrease was more evident after labeling of cells for 30 min (40% of the mean between the average profile of WT clones P9 and P26) than after labeling for 60 min (70%). By contrast, the labeling of M clone P8 was only slightly decreased compared with that of the WT clones (85 and 80% at 30 and 60 min, respectively). Mutation segregates with biochemical defects ofthe respiratory chain. We investigated the respiratory capacity of the cell clones by measuring the specific activities of two respiratory chain complexes, both containing mtDNA-encoded subunits (seven in complex I and three in complex IV), and the rate of oxygen consumption in intact cells. We did not normalize the respiratory chain activities for citrate synthase, because citrate synthase is also expressed at high levels in the rho0 mitochondria ofthe host cells. In six M clones and six WT clones, we also measured the concentration of lactic acid released in the culture medium at 48 h after plating.
As shown in Table I , results were significantly different between the M and the WT groups, clearly indicating defective respiration in the former compared with the latter. In particular, the mean value for oxygen consumption in the M group was 41% ofthe mean ofthe WT group (P < 0.0001 ); the mean value for lactic acid production in the M group was 218% of that ofthe WT group (P < 0.0001 ). The mean ofthe complex I activities in the M group was 63% of that in the WT group (P < 0.0001 ); the mean of the complex IV activities was 67% (P < 0.0005). The values for oxygen consumption and complex I and complex IV activities did not vary significantly between the WT group and the mean obtained from five cybrid clones derived from myoblasts of a normal subject (control group in Table I ). Lactate production was not measured in this group. In the only clone (PI I) with an intermediate amount of mutation, we measured only the oxygen consumption and found it similar to that of WT clones, suggesting that for the G3260 mu_ tation the threshold for detectable impairment of mitochondrial respiration is higher than 60% mutant mtDNA (Table I) . Given the high mutation rate and the great intraspecific variability of mtDNA, it is difficult to distinguish between pathogenic and nonpathogenic point mutations. The number of putatively pathogenic mtDNA mutations reported in the scientific journals has steadily increased in the recent past, making a thorough investigation of the normal variability of human mitochondrial genome as necessary as the identification oftrue or consensus mutations (14) (15) (16) (17) . There is general agreement that the pathogenicity ofa given mtDNA mutation should be based on the following criteria ( 18) all cybrid clones contain the same nuclear genotype ofthe host rho' cell line, mutations in the nuclear genes of the proband are ruled out. Likewise, this system eliminates the influence of the autochthonous nuclear genetic background on the expression ofthe phenotype associated with the mitochondrial mutation to be tested. In addition, availability of immortal clones containing different amounts of a given mitochondrial mutation makes it possible to study the genotype-phenotype relations in a quantitative way. Finally, cybrid clones containing homoplasmic wild-type mtDNA of the patients can be used as internal controls, eliminating the possibility that changes in the mtDNA other than the tested mutation may influence the expression of the cellular phenotype. We used transmitochondrial cybrids to confirm and to further characterize the pathogenicity of a heteroplasmic point mutation of mtDNA, the A G3260 transition, putatively responsible for the MIMyCa phenotype. To eliminate the intrinsic inaccuracy of densitometric measurement, SPMS was used as a highly reliable method to quantitate the amount of mutation. This analysis showed that the proportion of mutant and wild-type mtDNA of the massive transformant culture, measured after BrdU selection, was the result of the coexistence of two populations of cells, each containing a nearly homoplasmic population ofeither mutant or wild-type mtDNA. Mitotic segregation has been reported in myoblast clones harboring the G83I MERRF mutation by Boulet et al. (19) . However, in contrast with the latter study, the percentage of the MIMyCa mutation that we detected in the mass transformant culture (56% mutant mtDNA) differed from that measured in the original muscle biopsy of patient III-1 (90% mutant mtDNA), suggesting the presence in our cybrid system of negative selection against cells containing the mutation.
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The almost absolute mitotic segregation of the two mitochondrial genomes in our transformants suggests the existence oftwo distinct populations of mitochondria, each containing a homogeneous set of one or the other type of mtDNA (intraorganelle homoplasmy). A minority of mitochondria, containing a mixture ofwild-type and mutant genomes (intraorganelle heteroplasmy), could account for the only clone that remained stably heteroplasmic. However, intraorganelle homoplasmy could still be compatible with the coexistence of two populations of mitochondria in the same cell, i.e., interorganelle heteroplasmy.
Therefore, additional mechanisms must be hypothesized to explain the rarity of heteroplasmic clones observed in our study. According to one hypothesis, transformant cybrids could initially be heteroplasmic and could later undergo a rapid selection for either one ofthe two mitochondrial populations. However, we did not observe any time-dependent variation in the content of the G32W MIMyCa mutation after selection of the transformants and cell cloning. This result differs from the marked decrease in the content of the wild-type genome reported for both the G3243 mitochondrial encephalomyopathy lactic acidosis and strokelike episodes (20) Interestingly, the existence of a nearly homoplasmic mutant population of myogenic cells could give rise to areas ofthe muscle syncytium in which the respiratory capacity is markedly depressed. The regional impairment ofOXPHOS could in turn induce, as a compensatory phenomenon, the local proliferation of mitochondria, thus accounting for the ragged-red transformation of discrete areas of muscle fibers.
We have demonstrated that in our cybrid cell system the presence and the amount of the G3260 mutation correlate with defective mitochondrial respiration examined by biochemical analysis of complex I-and complex IV-specific activities, oxygen consumption rate, and lactic acid production. The increase of lactic acid levels is a sensitive index of a block in the aerobic utilization of pyruvate. Oxygen consumption and lactate production were the most discriminating tests between the M and WT groups. This is not surprising since both oxygen consumption and lactic acid production are indexes of the overall aerobic capacity ofthe cell; if, as in our case, multiple partial defects of the respiratory enzymes are present, their synergistic effect on the aerobic metabolism will result in marked alterations of these indexes. However, both complex I and complex IV were significantly defective as well.
Based on the above considerations and on our experimental results, we conclude that the A -> G 20 mutation is indeed pathogenic and that its presence alone is sufficient to explain the OXPHOS defects found in our MIMyCa patients ex vivo and, presumably, in vivo as well. Our conclusion is further supported by the recent identification of a British kindred harboring G32" in which several maternal members were affected by MIMyCa of variable severity (21 ). MIMyCa should therefore be considered a well characterized mitochondrial disease from both clinical and molecular-genetic standpoints.
Since the MIMyCa mutation affects a tRNA gene, it is likely that the molecular pathogenesis leading to the biochemical phenotype consists in the impairment of mitochondrial protein synthesis. This is supported by the demonstration of a generalized defect in mitochondrial translation in a clone nearly homoplasmic for the G3260 mutation.
Although the extent of [35SI methionine incorporation can vary widely among different mutant cell lines and from one experiment to another, it is interesting to note that in the experiment shown in Fig. 1 clone P28 had the lowest (2.3%) and clone P8 the highest (8.7%) percentages of wild-type A3211 in the M clone group. P28 showed a marked decrease in mitochondrial translation, while P8 showed only a slight decrease, suggesting that under our experimental conditions significant functional complementation for mitochondrial protein translation can occur in the presence of < 10% wild-type genome. This is in agreement with studies carried out in myoblast clones harboring the G831 MERRF mutation, which demonstrated that mitochondrial translation and complex IV activity were restored to near normal levels in the presence of an amount of wild-type mtDNA as low as 15-16%. However, the rise in incorporation of [35S]methionine in P28 after 60 min of labeling suggests the presence ofa defect in the rate oftranslation rather than in the steady state levels of mitochondrial protein synthesis. It is possible that shorter pulses of labeling may disclose a defect in incorporation also in clones with lower amounts of mutant G3260. 1106 Mariotti, Tiranti, Carrara, Dallapiccola, DiDonato, and Zeviani
